Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group
暂无分享,去创建一个
J. Steinberger | M. Hudson | S. Bhatia | M. Chen | W. Landier | M. J. Adams | D. Rosenthal | N. Marina | K. Meeske | K. Kinahan | S. Shankar | D. Hodgson
[1] D. Levy,et al. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). , 1992, The American journal of cardiology.
[2] D. Green,et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Silber,et al. Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors. , 2001, American heart journal.
[4] U. Saarinen-Pihkala,et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood , 2000, The Lancet.
[5] H. Bartelink,et al. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Thaler,et al. PRESENCE OF PROLONGED DISPERSION OF QT INTERVALS IN LATE SURVIVORS OF CHILDHOOD ANTHRACYCLINE THERAPY , 2002, Pediatric hematology and oncology.
[7] D. Faxon,et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echoca , 2003, Journal of the American College of Cardiology.
[8] S. Colan,et al. Cardiovascular trials in long-term survivors of childhood cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Lipshultz,et al. Pathophysiology of anthracycline‐ and radiation‐associated cardiomyopathies: Implications for screening and prevention , 2005, Pediatric blood & cancer.
[10] J. Thijssen,et al. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. , 2000, Ultrasound in medicine & biology.
[11] J. Kongerud,et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. , 1996, Heart.
[12] R. Winn,et al. The NCCN Guideline Program: a conceptual framework. , 1997, Oncology.
[13] J. R. Stewart,et al. Radiation injury to the heart. , 1995, International journal of radiation oncology, biology, physics.
[14] S. Lipsitz,et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. , 2004, The New England journal of medicine.
[15] Yan Liu,et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Nahata,et al. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. , 2000, Drug safety.
[17] D. V. Von Hoff,et al. Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.
[18] D. V. Von Hoff,et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. , 1977, The American journal of medicine.
[19] R. Olson,et al. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] Wan Ariffin Bin Abdullah,et al. Med Pediatr Oncol , 1999 .
[21] E. Pesonen,et al. Radiation-related chronic heart disease. , 1983, Chest.
[22] J. Collier. Dornase-alfa and orphan drugs , 1995, The Lancet.
[23] G. Levitt,et al. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Kevin C Oeffinger,et al. Chronic health conditions in adult survivors of childhood cancer. , 2006, The New England journal of medicine.
[25] A. D. Cunningham,et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population , 2001, Heart.
[26] R. Byhardt,et al. Dose and treatment factors in radiation related pericardial effusion associated with the mantle technique for Hodgkin's disease , 1975, Cancer.
[27] L. Constine,et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Schulz-Menger,et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. , 2001, American heart journal.
[29] R. Doll,et al. The Epidemiology of Cancer , 1980, Cancer.
[30] F. Bu'Lock,et al. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. , 1993, British heart journal.
[31] S. Hancock,et al. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Potter,et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] S. Tucker,et al. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. , 2003, International journal of radiation oncology, biology, physics.
[34] J. Silber,et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Pamela S Douglas,et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echoca , 2003, Circulation.
[36] R. Kronmal,et al. The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.
[37] K. Kip,et al. Is There a Potential Role for Serum Cardiac Troponin I as a Marker for Myocardial Dysfunction in Pediatric Patients Receiving Anthracycline-Based Therapy? A Pilot Study , 2001, Cancer investigation.
[38] P. Siltanen,et al. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease , 1987, Cancer.
[39] A. Massumi,et al. Radiation-induced valvular dysfunction. , 1983, Journal of the American College of Cardiology.
[40] M. Runge,et al. Doxorubicin-Induced Cardiomyopathy , 2000 .
[41] S. Hancock,et al. Asymptomatic cardiac disease following mediastinal irradiation. , 2003, Journal of the American College of Cardiology.
[42] H. von Melchner,et al. Adriamycin cardiotoxicity: a survey of 1273 patients. , 1979, Cancer treatment reports.
[43] S. Lipsitz,et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] L. F. Fajardo,et al. Radiation-induced heart disease: an update. , 1984 .
[45] C. Teinturier,et al. Diabetes mellitus after abdominal radiation therapy , 1995, The Lancet.
[46] P. Voûte,et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] G. Levitt,et al. Late anthracycline cardiotoxicity after childhood cancer , 2003, Cancer.
[48] P. Steinherz,et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.
[49] J. Gardin,et al. Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study , 2002, Annals of Internal Medicine.
[50] G. Martinelli,et al. Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.
[51] R. Brasseur,et al. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. , 1990, Biophysical chemistry.
[52] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[53] D. Green,et al. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] R. Carmel,et al. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications , 1976, Cancer.
[55] W. Strugnell,et al. Subendocardial late gadolinium enhancement in two patients with anthracycline cardiotoxicity following treatment for Ewing's sarcoma. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[56] S L Hancock,et al. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. , 1993, JAMA.
[57] F. Bu'Lock,et al. Increased risk of cardiac dysfunction after anthracyclines in girls. , 1995, Medical and pediatric oncology.
[58] R. D. de Winter,et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. , 2002, European journal of cancer.
[59] G. Levitt,et al. Does anthracycline administration by infusion in children affect late cardiotoxicity? , 2004, British journal of haematology.
[60] P. Levendag,et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[61] J. Björk,et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. , 2004, The Journal of clinical endocrinology and metabolism.
[62] M. Adamcová,et al. Anthracycline-induced cardiotoxicity. , 2000, Acta medica.
[63] H. Caron,et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. , 2006, European journal of cancer.
[64] M. Siimes,et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. , 1996, European journal of cancer.
[65] M. Hudson,et al. Hypothalamic Dysfunction After Chemotherapy , 2004, Journal of pediatric endocrinology & metabolism : JPEM.
[66] C. Pepine,et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. , 2003, JAMA.
[67] P. Kaufmann,et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[68] S. Lipsitz,et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] N. Gökçora,et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy , 2005, Pediatric blood & cancer.
[70] S. Wallace,et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.
[71] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[72] S. Hancock,et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] P. Dombernowsky,et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] S. Colan,et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.
[75] S. Lipsitz,et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. , 1997, Circulation.
[76] T. Spinks,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society The Effects of 10 Years of Recombinant Human Growth Hormone (GH) in Adult GH-Deficient Patients , 2022 .
[77] J. Silber,et al. Cardiac dysfunction following spinal irradiation during childhood. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] J. Gardin,et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. , 2001, Journal of the American College of Cardiology.
[79] J. Krischer,et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] P. Thompson,et al. Prevention of coronary artery disease in cancer patients , 2005, Pediatric blood & cancer.
[81] P. Voûte,et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[82] Yan Liu,et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] M. Knip,et al. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. , 1996, The Journal of clinical endocrinology and metabolism.
[84] L. Constine,et al. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease. , 1997, International journal of radiation oncology, biology, physics.
[85] J. Snowden,et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide , 2000, Bone Marrow Transplantation.
[86] Sara Rosenbaum,et al. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. , 2005, The American journal of cardiology.
[87] S. Lipsitz,et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] J. Pitha,et al. A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.
[89] Hung Q. Ngo,et al. On a hyperplane arrangement problem and tighter analysis of an error-tolerant pooling design , 2008, J. Comb. Optim..
[90] P. Dombernowsky,et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] J. Cayuela,et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] Daniel Levy,et al. The Epidemiology of Asymptomatic Left Ventricular Systolic Dysfunction: Implications for Screening , 2003, Annals of Internal Medicine.
[93] A. Tajik,et al. Constrictive Pericarditis in 26 Patients With Histologically Normal Pericardial Thickness , 2003, Circulation.
[94] V. Preedy,et al. Scottish Intercollegiate Guidelines Network , 2010 .
[95] A. Leenhardt,et al. Complete Atrioventricular Block Following Mediastinal Irradiation: A Report of Six Cases , 1991, Pacing and clinical electrophysiology : PACE.
[96] C. Carella,et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. , 1993, The Journal of clinical endocrinology and metabolism.